title: Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer.
abstract: CyberKnife (CK), hypofractionated stereotactic radiosurgery, is a preferred option for the treatment of advanced refractory lung cancer which is usually inoperable. Cytokine-induced killer (CIK) cell immunotherapy has a marked radiosensitization effect which aids the elimination of residual tumor cells in distant areas. The main purpose of the present study was to evaluate the clinical efficacy of CK alone and combined with CIK cell therapy for advanced refractory lung cancer. In one year, 22 patients with advanced lung cancer underwent CK therapy at a CyberKnife Center. Of these patients, 11 received CIK cell therapy before or after the CK therapy course. The median prescribed dose in the combined CK and CIK group was 35 Gy (mean, 33.8±5.0 Gy) with a median number of fractions of 5. The median dose for patients who underwent CK alone was 35 Gy (mean, 35.2±6.0 Gy). CIK cell therapy was administered according to the condition of each patient, generally 2 continuous therapeutic sessions in 2 months. The median follow-up period was 3 months. The preliminary curative efficiency rate was 81.82% for patients who underwent CK/CIK and 72.73% for those who received CK alone, according to radiographic re-examination (P>0.05). The median improvement in the Karnofsky scores of the CK/CIK group was 20 (18±10.51) compared with 10 (8.6±11.85) for those who underwent CK alone (P<0.05). The median expression of carcinoembryonic antigen (CEA) before and after treatment was 40.81 and 12.21 ng/ml, respectively, for the CK/CIK group compared with 39.04 and 26.36 ng/ml for CK alone. The median percentage of phenotype expression of the CIK cells (CD3(+)/CD8(+) and CD3(+)/CD56(+)) in the patients who underwent CK/CIK was recorded as 64.35% (57.08±16.94%) and 15.27% (18.80±7.00%), respectively, prior to transfusion. The preliminary results of the present study suggest that CK combined with CIK cell immunotherapy improved the short-term outcomes of patients for curative efficacy, Karnofsky scores, tumor marker levels and immune status compared with alternative CK treatments, although further studies are required.
authors: School of the Integration of Traditional and Western Medicine, Binzhou Medical University, Yantai, Shandong 264003;
authors: Yuan-Yuan
authors: YY
authors: Wang
authors: Yi-Shan
authors: YS
authors: Wang
authors: Tao
authors: T
authors: Liu
authors: Ke
authors: K
authors: Yang
authors: Gui-Qing
authors: GQ
authors: Yang
authors: Han-Chen
authors: HC
authors: Liu
authors: Shan-Shan
authors: SS
authors: Wang
authors: Jia-Lin
authors: JL
authors: Yang
keywords: CyberKnife; clinical efficacy; cytokine-induced killer; immunotherapy; stereotactic radiosurgery
references: Technol Cancer Res Treat. 2010 Dec;9(6):589-96
references: 21070081
references: J Thorac Oncol. 2007 Aug;2(8):706-14
references: 17762336
references: Cancer Biother Radiopharm. 2009 Feb;24(1):91-8
references: 19243251
references: Exp Ther Med. 2012 May;3(5):845-852
references: 22529877
references: J Hematol Oncol. 2010 Oct 22;3:39
references: 20969774
references: Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):323-7
references: 20832663
references: Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):297-303
references: 19362249
references: Blood. 2001 May 15;97(10):2923-31
references: 11342413
references: Lung Cancer. 2003 Jul;41(1):1-11
references: 12826306
references: South Med J. 2008 Apr;101(4):376-82
references: 18360342
references: Oncol Rep. 2009 Mar;21(3):693-6
references: 19212628
references: Ann Thorac Surg. 2003 Apr;75(4):1097-101
references: 12683544
references: Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):277-84
references: 20004530
references: Ann Hematol. 1997 Feb;74(2):51-6
references: 9063373
references: J Appl Clin Med Phys. 2010 Jan 29;11(1):3142
references: 20160699
references: Exp Hematol. 2005 Dec;33(12):1427-35
references: 16338484
references: J Hematol Oncol. 2009 Jan 17;2:1
references: 19149899
references: Cancer Radiother. 2008 Dec;12(8):793-9
references: 18706844
references: Exp Ther Med. 2011;2(1):21-26
references: 21494319
references: Comput Aided Surg. 2007 Sep;12(5):253-61
references: 17957532
references: Cancer Immunol Immunother. 2000 Aug;49(6):335-45
references: 10946816
references: JAMA. 2010 Mar 17;303(11):1070-6
references: 20233825
references: J Exp Med. 1991 Jul 1;174(1):139-49
references: 1711560
references: J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10
references: 20407789
references: Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7
references: 15744236
references: Cancer Radiother. 2010 Oct;14(6-7):438-41
references: 20724188